|
2.11 Etiologie - Alimentation
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.5 ASCO
|
|
|
|
5.5.1 ASCO (général)
|
|
|
ASCO 2018 Preview [OBR blog]
|
|
|
|
|
|
Topics
covered included a practice-changing regimen for T-cell malignancies,
shorter course trastuzumab for early HER2-positive breast cancer,
cost-effectiveness of next-generation sequencing, mobile sensor
technology for reducing symptom severity in head and neck cancer
survivors, and alarmingly low rates of lung cancer screening in heavy
smokers and former heavy smokers. Here are recaps of the major findings.
|
|
|
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
|
|
|
|
|
|
|
|
|
5.5.10 ASCO (hémato)
|
|
|
|
New Regimens Improve Survival for Children and Young Adults With T-Cell Cancers [ASCO]
|
|
|
|
|
|
In
a federally funded, randomized phase III clinical trial performed by
the Children’s Oncology Group (COG), 90% of children and young adults
with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic
lymphoma (T-LL) were alive four years after starting treatment regimens
on this trial, and 84% were cancer free. These are the highest survival
rates for these T-cell malignancies reported to date, according to the
authors.
|
|
|
|
|
|
|
5.5.13 ASCO (divers)
|
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
|
|
Shorter Trastuzumab Treatment for HER2+ Breast Cancer Can Be as Effective, With Fewer Cardiac Side Effects [ASCO]
|
|
|
|
|
|
A
phase III randomized clinical trial of 4,089 women with HER2-positive,
early-stage breast cancer found that taking trastuzumab (Herceptin) for 6
months was non-inferior to the current standard of 12 months. The
disease-free survival rate at four years was 89.4% with 6 months of
therapy and 89.8% with 12 months of therapy. In addition, only 4% of
women in the 6-month arm stopped trastuzumab early because of cardiac
problems, compared with 8% in the 12-month arm.
|
|
|
|
|
|
|
Shorter drug treatment OK for many breast cancer patients [AP]
|
|
|
|
|
|
“There’s
no reason to not immediately change practice. The findings are
persuasive,” said Dr. Richard Schilsky, chief medical officer for the
oncology society. Most of Herceptin’s cancer-fighting benefit seems to
come in the early months of use, he said.
|
|
|
|
|
|
|
|
|
5.5.8 ASCO (poumon)
|
|
|
|
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
6.1 Observation
|
|
|
Why Is Liver Cancer on the Rise? [Cancer Research Catalyst]
|
|
|
|
|
|
The
study attributed about 22 percent of liver cancer deaths to cigarette
smoking. Obesity is another driving force. Previous research has found
that from 2000 to 2003, about 26 percent of liver cancer cases were
attributable to excess body weight; from 2008 through 2011, body weight
could be linked to about 36 percent of liver cancer cases that occurred.
Alcoholism and nonalcoholic steatohepatitis, a type of severe fatty
liver disease, are also risk factors.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.6 Publications
|
|
|
|
|
Nine pitfalls of research misconduct [Nature]
|
|
|
|
|
|
C.K.G.
coined the mnemonic TRAGEDIES (Temptation, Rationalization, Ambition,
Group and authority pressure, Entitlement, Deception, Incrementalism,
Embarrassment and Stupid systems) to capture the interlocking factors
that can lead scientists astray.
|
|
|
|
|
|
|
Give every paper a read for reproducibility [Nature]
|
|
|
|
|
|
In
2012, I saw an advertisement for an unusual new role, and knew I was
the one for the job. Leaders at the Cancer Research UK Beatson
Institute, a non-profit organization in Glasgow, had created a position
to weave discussion of and practices for research integrity into the
daily routines of its roughly 300 researchers.
|
|
|
|
|
|